Rocket Pharmaceuticals
RCKT
81 hedge funds and large institutions have $751M invested in Rocket Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 34 increasing their positions, 18 reducing their positions, and 13 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 18
21% more capital invested
Capital invested by funds: $622M → $751M (+$129M)
6% more call options, than puts
Call options by funds: $2.63M | Put options by funds: $2.48M
0.11% more ownership
Funds ownership: 94.94% → 95.04% (+0.11%)
7% less funds holding
Funds holding: 87 → 81 (-6)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$7.43M |
| 2 |
Millennium Management
New York
|
+$6.24M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.39M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.31M |
| 5 |
Morgan Stanley
New York
|
+$4.09M |
Top Sellers
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$7.89M |
| 2 |
HCM
Highline Capital Management
New York
|
-$6.07M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.98M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.88M |
| 5 |
BM
Bridger Management
New York
|
-$3.53M |
RCKT Hedge Fund Activity: Q1 2019 in Review
81 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2019, worth a combined $751M — up 21% from $622M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of RCKT and 8 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 34 added.
The largest buyer was State Street, adding an estimated $7.43M. The largest seller was Boxer Capital, cutting an estimated $7.89M.
- 81 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2019, down from 87 in Q4 2018.
- Funds reported $751M of Rocket Pharmaceuticals stock for Q1 2019, up 21% quarter-over-quarter.
- 8 funds opened new Rocket Pharmaceuticals positions in Q1 2019 and 13 closed out, a net change of -5 holders.
- The largest Rocket Pharmaceuticals buyer in Q1 2019 was State Street, an estimated $7.43M added.
- The largest Rocket Pharmaceuticals seller in Q1 2019 was Boxer Capital, an estimated $7.89M sold.
Based on aggregated 13F filings for Q1 2019.